Boston Scientific Corp. (BSX) reported strong third-quarter 2025 results, exceeding analyst expectations on both revenue and earnings. The company’s broad-based growth was driven by robust performance in its Cardiovascular and MedSurg segments, supported by product innovation and expanding global demand.
Q3 Revenue Climbs 20% to $5.07B as EPS Beats Estimates at $0.75
Boston Scientific Corp. (BSX) reported a remarkable performance in the third quarter of 2025, with net sales reaching $5.065 billion. This marks a 20.3% increase on a reported basis compared to the same period last year. The company’s GAAP net income attributable to common stockholders was $755 million, translating to $0.51 per share, a notable improvement from $469 million or $0.32 per share a year ago. The adjusted EPS stood at $0.75, surpassing the expected EPS of $0.71. These results highlight the company’s ability to exceed market expectations and deliver robust growth.
In terms of segment performance, the Cardiovascular segment led the charge with a 22.4% reported growth, while the MedSurg segment followed with a 16.4% increase. The U.S. market showed a substantial 27% growth, contributing significantly to the overall performance. However, the EMEA region faced challenges, with only a 2.6% reported growth and a decline of 2% on an operational basis. Despite these regional disparities, the overall performance was strong, driven by strategic initiatives and innovative products.
CEO Mike Mahoney attributed the success to the company’s strategic focus on innovation and global team efforts. The company managed to outperform its guidance range for net sales growth, which was initially set between 17% to 19% on a reported basis. This achievement underscores the company’s effective execution of its growth strategy and its ability to navigate market challenges successfully.
BSX Targets High-Teens Revenue Growth With Expanded Portfolio
Looking ahead, Boston Scientific Corp. has provided optimistic guidance for the full year and the fourth quarter of 2025. The company estimates full-year net sales growth to be approximately 20% on a reported basis and 15.5% organically. The expected GAAP EPS is projected to range from $1.97 to $2.01, while the adjusted EPS is anticipated to be between $3.02 to $3.04. These projections indicate a strong finish to the year, driven by continued innovation and strategic market expansion.
For the fourth quarter, the company forecasts net sales growth in the range of 14.5% to 16.5% on a reported basis, with organic growth expected between 11% to 13%. The GAAP EPS for the quarter is expected to be between $0.48 to $0.52, with adjusted EPS ranging from $0.77 to $0.79. This guidance reflects the company’s confidence in maintaining its growth trajectory through strategic initiatives and product launches.
Boston Scientific’s strategic acquisitions and product innovations play a crucial role in its growth outlook. Recent developments, such as the PMDA approval in Japan for the FARAPULSE™ Pulsed Field Ablation System and the commencement of the AGENT DCB STANCE trial, highlight the company’s commitment to expanding its product offerings. Additionally, the acquisition of Elutia, Inc. and the agreement to acquire Nalu Medical, Inc. are expected to bolster the company’s portfolio and enhance its market position. These strategic moves align with the company’s long-term vision of delivering innovative medical solutions and driving sustainable growth.